Pfizer, Merck KGaA throw in the towel on another Bavencio PhIII as once bright hopes shrivel fast

Pfizer and Merck KGaA have hit the trifecta for PD-L1 failure in ovarian cancer.

The two partners said late today that they are shuttering the Phase III JAVELIN Ovarian PARP 100 study, their third straight fail in the ovarian cancer sector in recent months.